Connecticut

The 2021 study obligation and DMHAS report were the first major steps. The Feb 2022 report explicitly discussed Yale as a potential pilot lead and described how a programme could position Connecticut within the psychedelic-services landscape while still requiring research design, IRB review, FDA submission, drug supply arrangements and funding.###

Connecticut has also seen broader reform pressure. HB 7065, concerning decriminalisation of possession of small amounts of psilocybin, passed the House on 19 May 2025 and was then reported favourably and tabled for the Senate calendar on 20 May 2025, but this review did not identify enactment. It should therefore be treated as a significant but unsuccessful or incomplete legislative step, not current law.###

In 2026, SB 191 sought to expand access to and extend the psychedelic-assisted therapy pilot programme. The bill analysis says it would expand eligibility for the DMHAS pilot, and the official bill-status page shows Senate passage on 8 Apr 2026, House passage on 6 May 2026, and an “In Concurrence” status on 6 May 2026. As of 15 May 2026 it should be treated as passed by both chambers but not yet clearly enacted.###

Connecticut’s verified research centre of gravity is Yale-linked and publicly connected to the state pilot. The DMHAS digest identifies a Psychedelic Pilot Program site at 40 Temple Street operating through a DMHAS/Yale staffing contract, while the earlier DMHAS study report repeatedly references Yale as the natural programme partner.###

That makes Connecticut unusual: its most important verified activity is neither a pure commercial trial-site story nor a classic decriminalisation story, but a state-supported, academically linked pilot infrastructure. For a professional audience, that is more relevant than trying to infer a large local trial market that has not been verified in the sources used here.###

Connecticut should therefore be characterised as a policy-and-pilot state with a concentrated Yale/DMHAS footprint rather than as a broad regional research hub with multiple independently verified psychedelic trial sites.###

Implementation sits chiefly with DMHAS, not with a consumer-market regulator. The 2022 report laid out the practical prerequisites for a pilot; the 2024-25 DMHAS digest then confirmed that a research programme site had in fact been established and was administering psychedelic treatments through the DMHAS/Yale arrangement.###

Because this is a pilot structure, the important implementation questions are eligibility, funding continuity, protocol design, staffing and possible interaction with future federal approvals. SB 191 is best read as an effort to preserve and broaden the existing pilot rather than to create a general psilocybin services market.###

Operationally, that means access remains capacity-limited and programme-dependent. Publication should avoid any implication that Connecticut has a standing statewide network of facilitators, service centres or licensed psychedelic businesses.###

Connecticut’s verified ecosystem is narrow but meaningful. Yale and the Connecticut Mental Health Center are the principal named institutional anchors in the official materials reviewed here, and DMHAS is the key state actor.###

That ecosystem is currently more public-sector and academically mediated than commercial. For researchers, policy stakeholders and patient-access analysts, Connecticut is best understood as an East Coast pilot jurisdiction testing a tightly governed public-health model rather than building a broad private-market ecosystem.###

Because the public record here is concentrated in official programme documents and bills, any additional clinic, non-profit or conference claims should be manually verified before publication rather than inferred.###

Over the next 12 to 24 months, Connecticut’s trajectory depends more on whether it preserves, funds and expands its pilot than on whether it pivots suddenly into a Colorado-style services framework. If SB 191 or successor legislation is enacted, the pilot could broaden eligibility and stabilise the programme’s legal footing.###

Patient access is likely to remain selective and programme-bound rather than open-market. Reimbursement questions may develop differently in Connecticut because the state already has a public-sector pilot component, but as of this review there is no verified broad reimbursement regime for psychedelic-assisted therapy beyond ordinary ketamine/esketamine pathways and the pilot’s own support structure.###